Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

Human gene therapy

Volumn 14, Issue 3, 2003, Pages 306-309

  Song, Jonathan C ^a   McDonnell, Peter J ^a   Gordon, Erlinda M ^a   Hall, Frederick L ^a   Anderson, W French ^a  

^a DOHENY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN G; CYCLINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORNEA OPACITY; DOSE RESPONSE; FEMALE; GENE VECTOR; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RETROVIRUS;

ADOLESCENT; ADULT; AGED; CORNEAL OPACITY; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; RETROVIRIDAE;

EID: 0141560775     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)